MassDevice Q&A: Amar Sawhney

Amar Sawhney has a knack for turning gel into gold.

Over the years, the serial entrepreneur managed to leverage his work in hydrogel technology at the University of Texas into the basis for six companies, including one snapped up by Genzyme early in the decade and another that Covidien predecessor Tyco Healthcare acquired in 2006.

Now the 42-year-old is looking to take a new venture, I-Therapeutix, to the next level. It’s also using hydrogels — water-based biodegradable liquids that morph into solids in the body — to develop the I-Zip ocular bandage for healing incisions in the eye after surgery. The bandage is applied as a liquid, but changes into a soft, protective barrier which then breaks down into tears when the therapy is complete.

MassDevice caught up with Sawhney this week to discuss his background, how he made the transition from inventor to CEO and his take on the regulatory and economic landscapes for the medical device industry.

MassDevice: What was your first job?

Amar Sawhney: It was a startup called Focal Inc. I started based on my graduate work in 1992 at the University of Texas. I never really had a job, so I had to build my own. I was the technology founder, not the CEO. Focal went public in 1997 and was sold to Genzyme [in 2001], but I had left by then. I was involved in the IPO but not in the sale; by then I had gone on to start Confluent Surgical.

MassDevice: So your first job was a company you started? How’d you know how to run a company?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Khosravi_Fred_100x100.jpg}AS: I started out as a technical guy and of necessity I have become a chief executive. You have to know the business side to start a company. Luckily, I have my friend Fred Khosavri, who is a serial entrepreneur on the West Coast who has served as a mentor for me. We collaborate on all our ventures now.

But starting Focal was a great experience for me. I had to get a job, so I had to start my own company. When things look like they’re unfortunate, it can also be the best thing that ever happened to you. A lot of my colleagues found good careers, but I have been lucky enough to do this.

MassDevice: What’s the biggest takeaway from doing business during this recession?

AS: You have to stay true to fundamentals: Being capital-efficient, being innovative and executing rapidly. If you are true to the fundamentals, capital will always be available and you will not be leveraging any bubble.

Don’t ride waves, because sometime they’re up but they always go down. Too many people get fascinated by the bubbles. When we started Confluent, it was during the Internet bubble. Everybody was running after the latest Internet play, but we were building a successful medtech company with good products.

I don’t raise money because of of my track record. I do it only on an as-needed basis. That’s why we get appropriate valuations. If you don’t become part of these extreme events, than you won’t get dragged down when the extreme events fail.

MassDevice: What long-term effects will the recession have on your business? Will those stick, or can you wait out the storm and go back to business as usual?

AS: We build companies not only to get acquired, but to build businesses that make money in the long term. They’re not just a flash in the pan.

So when questions get asked about healthcare reform and these flash-in-the-pan events, I say, “If you have solid products helping patients improve the quality of life, improve health and reduce mortality, then those products will never go out of fashion.”

Unfortunately, the world tends to ride waves and that can be very seductive. Yes, innovation comes from waves, but sometimes they get over-capitalized and that creates wasteful habits.

A good example is some of the biotech companies that are stumbling around in need of more funding — it creates a “downer” environment. So in this environment lots of good ideas will not get funded, because of mistakes made by irrational levels of funding people did in the heyday.

MassDevice: What advice do you have for people with great ideas who can’t get funding?

AS: They can take comfort in the fact that you can continue to incubate in an academic setting, or wait until the storm passes. It’s always good to launch, but you also have to balance that with waiting for a good environment because entry is fragile. A lot of this is confidence; the actual crisis will take time to flush out of the system, but confidence will go up soon.

MassDevice: We’re in a period of great flux in the medical industry. What do you think it will look like in 20 years?

AS: There are things that have gotten out of control and now the reaction is swinging back on the community. A lot of orthopedic and spine companies were resorting to questionable practices; consequently, the onus is on the healthcare reform effort, which is putting a big burden on companies to comply with new rulings. [The gift ban] is a huge burden on companies. It will make it difficult for Massachusetts companies, because everyone is penalized for the action of a few unscrupulous players.

These new rules are changing the way we do things. Innovation will not go out of fashion, but in an environment where we can’t pay for these new innovations it’s going to be difficult to push forward. There will be changes in the healthcare system, probably where the government provides a base minimum for care. We see that in optometry with procedures like Lasik, where people pay out of pocket for it. I think there will be two poles of healthcare that may evolve towards the government paying base level and if you want premium you’ll pay out-of-pocket.

Innovation will still be there, but how you pay for it will have to change. The biggest barrier to getting markets innovated is not technology, it’s not regulation; it’s reimbursement and getting it paid for.

If you make the greatest device in the world but nobody can pay for it, what are you going to do?

There will always be people pushing the boundary, but how they will get paid will affect what devices are available. There’s no limit to human ingenuity, but it has to have a framework and checks and balances.

MassDevice: How have regulatory rule changes affected training a salesforce?

{IMAGELEFT:http://www.massdevice.com/sites/default/wp-content/uploads/headshots/Sawhney_Amar_100x100.jpg}AS: As we get into selling our products, the code of ethics needs to be robustly explained. You can’t do what orthopedic and spine companies have done. You can explain the product, but you cannot pay them to use the product. There have to be clear boundaries. The products have to stand on their own. But the level of enforcement is making it very difficult.

It’s going to be problematic, but we are still planning to be in compliance. The companies with products already in play will have a tougher time with compliance than a company like ours, which is just starting commercialization. Those companies will spend more energy doing this stuff.

It’s like Sarbanes-Oxley in that way for small companies. Sarbanes-Oxley made it very difficult to access to public markets. There is no doubt that something needs to be done, but when pendulum swings it tends to swing to the extreme.

MassDevice: When you’re building a team today, what are your focus areas — R&D, regulatory, sales and marketing, operations?

AS: It varies. When you’re getting started, you need to make sure you have a good R&D, but at the same time you need good operations people. Companies that don’t have that have a very high level of difficulty. It’s like Organogenesis, which made a great product, but they made it at a price that was higher than they could sell it at. So you have to have good operations. We do cost-of-goods analysis at a very early stage to make sure the product can be profitable. You also need good marketing, because you have to get feedback from your customers.

MassDevice: What rules or regulations have you the most concerned?

AS: Sarbanes-Oxley is always out there, because there are only three ways to get to some kind of sustainability. One of them is to sell it, two is to take it public, or three is to build a sustainable, profitable company. Sarbanes-Oxley makes it very difficult to take your company public.

MassDevice: Will the industry ever go from the face-to-face transactions gift bans make so difficult to something that can be done online?

AS: No, not really. These are procedure-specific products. It’s not pills. For years pharma wanted pills and injections that could be done the same way, without training the physicians. But medical devices need training and hand-holding and often the design is improved with physician feedback, so that loop is much more critical for medical device companies. Pharma needs the link with academia and the laboratories; medical devices need the link with physicians.

RSS From Medical Design & Outsourcing

  • Drug Deactivation program roll out to all facilities for safe disposal of unused prescription medications
    Verde Technologies announced that New Brighton-based Meridian Behavioral Health, the largest for-profit substance abuse and addiction treatment group in Minnesota, has become its most recent partner in the deactivation and safe disposal of prescription medications including methadone. Meridian is the first behavioral health group to roll out the Deterra Drug Deactivation System to all 17 […]
  • Lophius Biosciences introduces T-activated ImmunoScan Cocktail
    Lophius Biosciences announced the commercial launch of T-Track ImmunoScan and T-activated ImmunoScan Cocktail. Based on a proprietary and very specific cocktail of stimulants in combination with the Company’s T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. T-Track ImmunoScan and the T-activated […]
  • Cosasco’s wireless communications protocol makes electrically hazardous areas safer
    Cosasco has expanded the functionality of its CWT-9020 wireless water system corrosion monitor for electrically hazardous areas by offering ISA100 Wireless communications protocol. Along with WirelessHART 7, the new protocol option allows the transmitter to integrate with an even wider range of existing wireless systems. ISA100 Wireless supports more wireless devices and provides an effective […]
  • Vicon captures a new development in motion capture (mocap)
    Vicon announced the launch of its new flagship camera platform, the Vicon Vantage. Drawing on over 30 years’ of motion capture (mocap) experience, the Vantage platform combines innovative technology with accessible design to open up motion capture to a broader audience. Vicon is a motion capture technology specialist company for science and life industries. Advances in […]
  • Satel’s latest product sets a new milestone in radio manufacturing
    The new Satelline TR4, from the Finnish manufacturer of radio data transmission systems, Satel sets a new milestone. The compact UHF transceiver with transmitting power of 1,000 mW is compatible with the protocols of Pacific Crest, Trimble and Satel. The type certifications in all important regions of the world make the TR4 ideal for integration […]
  • SCHURTER announces retirement of founder and management changes
    SCHURTER announced the retirement of founder Bruno H. Schurter on June 29, 2015. The company, founded in 1982 in Petaluma, California, will change management effective July 1, 2015. Bruno H. Schurter, president and CEO will retire after 33 years of heading up the privately held company, which is a subsidiary of SCHURTER Holding AG, founded in […]
  • Silicone: Expanding the horizon for modern medical devices
    Editor’s note: This article comes from Albright Technologies a manufacturer of custom silicone prototypes and provides volume production for medical, pharmaceutical, industrial, and other applications. Silicone materials have been around for more than 70 years. Beginning in the 1960s, silicones have played an important and evolving part in products designed for the medical field. Since that time, […]
  • DeNovo Sciences appoints a molecular diagnostics veteran as new CSO
    DeNovo Sciences, a producer of  liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s […]
  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]

Leave a Reply